<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
xmlns="http://purl.org/rss/1.0/"
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
xml:lang="en">
<channel rdf:about="http://www.takeda.com/irnews/index.rss">
 <title>Takeda Pharmaceutical Company Limited</title>
 <link>http://www.takeda.com/</link>
 <description>IR News</description>
 <items>
  <rdf:Seq>
  <rdf:li rdf:resource="http://www.takeda.com/press/article_29939.html" />
  <rdf:li rdf:resource="http://www.takeda.com/press/article_29936.html" />
  <rdf:li rdf:resource="http://www.takeda.com/investor-information/quarterly-results/article_16229.html" />
  <rdf:li rdf:resource="http://www.takeda.com/press/article_29632.html" />
  <rdf:li rdf:resource="http://www.takeda.com/press/article_29574.html" />
  </rdf:Seq>
 </items>
</channel>
<image rdf:about="http://www.takeda.com/favicon.ico">
 <title>Takeda Pharmaceutical Company Limited</title>
 <link>http://www.takeda.com/</link>
 <url>http://www.takeda.com/favicon.ico</url>
 <description>icon</description>
</image>
<item rdf:about="http://www.takeda.com/press/article_29939.html">
 <title>Takeda Completes Acquisition of Millennium</title>
 <link>http://www.takeda.com/press/article_29939.html</link>
 <description></description>
 <dc:date>2008-05-15</dc:date>
</item>
<item rdf:about="http://www.takeda.com/press/article_29936.html">
 <title>Takeda Completes Subsequent Offering Period for Shares of Millennium Pharmaceuticals, Inc.</title>
 <link>http://www.takeda.com/press/article_29936.html</link>
 <description></description>
 <dc:date>2008-05-15</dc:date>
</item>
<item rdf:about="http://www.takeda.com/investor-information/quarterly-results/article_16229.html">
 <title>Analysts meeting on results for FY2007 was published.</title>
 <link>http://www.takeda.com/investor-information/quarterly-results/article_16229.html</link>
 <description>　</description>
 <dc:date>2008-05-12</dc:date>
</item>
<item rdf:about="http://www.takeda.com/press/article_29632.html">
 <title>Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period</title>
 <link>http://www.takeda.com/press/article_29632.html</link>
 <description>OSAKA, Japan, and CAMBRIDGE, Mass., USA, May 9, 2008 – Takeda Pharmaceutical Company Limited (“Takeda”, TSE: 4502) and Millennium Pharmaceuticals, Inc. (“Millennium”, Nasdaq: MLNM) today announced the successful completion of Takeda’s cash tender offer by its wholly-owned subsidiary, Mahogany Acquisition Corp., to acquire all outstanding shares of Millennium common stock for US$25.00 per share. The initial offering period for the tender offer expired at 12:00 midnight, New York City Time, at the end of Thursday, May 8, 2008.  The depositary for the tender offer has advised Takeda that, as of the expiration of the initial offering period, 300,871,367 shares of Millennium common stock have been tendered, representing approximately 91.9% of the outstanding shares of Millennium common stock (of which 26,917,513 shares, or approximately 8.2% of the outstanding shares, were tendered under guaranteed delivery procedures). All shares that were validly tendered and not withdrawn (excluding shares tendered under guaranteed delivery procedures) have been accepted for purchase, and Takeda will promptly pay for all such shares.  Shares validly tendered in satisfaction of guaranteed delivery procedures will also be accepted for payment and promptly paid for.</description>
 <dc:date>2008-05-09</dc:date>
</item>
<item rdf:about="http://www.takeda.com/press/article_29574.html">
 <title>Notice regarding Acquisition of the Company’s own shares (Under the provisions of Articles of Incorporation pursuant to Article 165 (2) of the Corporation Law of Japan) </title>
 <link>http://www.takeda.com/press/article_29574.html</link>
 <description>OSAKA, Japan, May 9, 2008 --- Takeda Pharmaceutical Company Limited (“Takeda”) announced that its Board of Directors resolved today acquisition of its own shares under Article 156 of the Corporation Law of Japan, as applied pursuant to Article 165 (3) of the Corporation Law, as detailed below:</description>
 <dc:date>2008-05-09</dc:date>
</item>
</rdf:RDF>
